Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between Farydak and Orthoclone OKT3

Results for the following 2 drugs:
Farydak (panobinostat)
Orthoclone OKT3 (muromonab-cd3)

Interactions between your drugs

There were no interactions found in our database between Farydak and Orthoclone OKT3 - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Farydak

A total of 868 drugs are known to interact with Farydak.

Orthoclone OKT3

A total of 131 drugs are known to interact with Orthoclone OKT3.

Drug and food interactions

Moderate

panobinostat food

Applies to: Farydak (panobinostat)

Do not consume grapefruit, grapefruit juice, star fruit, pomegranate, or pomegranate juice during treatment with panobinostat. Doing so can increase blood levels of the medication. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; fatigue; swelling in the arms or legs; heart problems (e.G., chest pain, heart failure, irregular heartbeat); liver problems; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide